InvestorsHub Logo
Followers 827
Posts 119579
Boards Moderated 14
Alias Born 09/05/2002

Re: DewDiligence post# 738

Friday, 10/27/2023 8:34:52 AM

Friday, October 27, 2023 8:34:52 AM

Post# of 751
ABBV reports 3Q23 results—raises_2023 non-GAAP EPS guidance:

https://news.abbvie.com/news/press-releases/abbvie-reports-third-quarter-2023-financial-results.htm

The new 2023 non-GAAP EPS guidance is $11.19-11.23 (up from the prior range of $10.90-11.20). The sharp decline from 2022’s non-GAAP EPS of $13.77 is due to the launch of Humira biosimilars in the US market.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ABBV News